The United States drug agency has authorized that children between the ages of twelve and 15 can receive a third dose of the COVID-19 vaccine developed by Pfizer and BioNTech, within a review that also includes a reduction from six to five months the time frame to have this booster injection.
The changes also contemplate the provision of a third dose for immunosuppressed children between the ages of five and eleven, according to the Food and Drug Administration (FDA), which assumes that there are no risks that advise against further progress in the immunization campaign among the child population.
The acting head of the FDA, Janet Woodcock, has highlighted in a statement that it is “key” to continue taking measures against the virus after the irruption of the omicron variant and has advocated not only for completing the vaccination, but also for carrying mask and respect social distance.
The United States has recorded more than 55 million COVID-19 cases and about 826,000 deaths since the start of the pandemic, according to data compiled by Johns Hopkins University. The arrival of omicron has boosted infections in recent weeks, with daily averages that are above 350,000.